MeDucation· @MeDucationai · X·· 4 天前评分45
正文 · 机器翻译
把 @VivekSubbiah 的 #ESMO26 关于“攻克不可成药靶点”的演讲列入必看清单。给 fellows 的金句：KRAS G12C 从不可成药变成已获批，靠的是锁定非活性 GDP 结合态；下一波则瞄准活性 RAS(ON) 状态。
584 浏览 · 4 赞 · 1 转发 · 0 回复
会议摘要
Calderasib monotherapy in various KRAS G12C–mutated advanced solid tumors: Results from the phase 1 KANDLELIT-001 study
https://esmocongress.esmo.orgKrascendo 3: A randomised, phase III trial in progress of divarasib vs immunotherapy or observation in patients with resected, stage II-IIIB, KRAS G12C+ non-small cell lung cancer
https://esmocongress.esmo.org2683P按 NSCLC, metastatic 对上
First-line (1L) olomorasib + pembrolizumab in KRAS G12C-mutant NSCLC: Updated results from LOXO-RAS-20001 and SUNRAY-01
https://esmocongress.esmo.org📍Don’t miss the lecture @myESMO #ESMO26 “Drugging the undruggables: The next wave of targeted therapies” @OncoAlert @oncodaily Link - https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal/show/session/177在 X 查看被引用的帖子
来源：MeDucation · x.com